×
About 20,656 results

ALLMedicine™ Parkinson Disease Center

Research & Reviews  9,881 results

"My Body Does Not Fit in Your Medical Textbooks": A Physically Turbulent Life With an U...
https://www.ncbi.nlm.nih.gov/pubmed/33620331
Advances in Mind-body Medicine; Snapp M

Feb 23rd, 2021 - The purpose of this article is to enhance our understanding of prayer healing by studying a case which was described as a 'remarkable healing' by a medical assessment team at the Amsterdam University Medical Centre (UMC) in the Netherlands. This r...

Association of autonomic symptoms with cerebrospinal fluid biomarkers in Parkinson dise...
https://doi.org/10.1097/MD.0000000000024837
Medicine Yu Z, Li Y et. al.

Feb 20th, 2021 - Dysautonomia is common in patients with Parkinson disease (PD) since disease early phase. Scales for Outcomes in Parkinson's disease - Autonomic (SCOPA-AUT) is a well-designed scale assessing the autonomic dysfunctions of PD patients. Our objectiv...

Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation...
https://doi.org/10.1016/j.parkreldis.2021.02.003
Parkinsonism & Related Disorders; Kopytova AE, Rychkov GN et. al.

Feb 20th, 2021 - Mutations in the glucocerebrosidase gene (GBA) encoding the lysosomal enzyme glucocerebrosidase (GCase) cause Gaucher disease (GD) and are the most commonly known genetic risk factor for Parkinson disease (PD). Ambroxol is one of the most effectiv...

Attitudes toward use and timing of deep brain stimulation: a patient's with DBS perspec...
https://doi.org/10.1016/j.clineuro.2021.106553
Clinical Neurology and Neurosurgery; Cabrera LY, Mitchell SD et. al.

Feb 20th, 2021 - To guide responsive policy and better understand factors that might shape patients' decisions to have DBS earlier, we explore perspectives and attitudes toward earlier deep brain stimulation (DBS) of Parkinson disease (PD) patients with DBS. Befor...

Tumor Necrosis Factor Inhibition and Parkinson Disease: A Mendelian Randomization Study.
https://doi.org/10.1212/WNL.0000000000011630
Neurology Kang X, Ploner A et. al.

Feb 20th, 2021 - To evaluate the effects of long-term tumor necrosis factor (TNF) inhibition on the risk and age at onset of Parkinson disease (PD), we performed a two-sample Mendelian randomization study using genome-wide association studies (GWAS) summary statis...

see more →

Guidelines  155 results

Gocovri Clinical Data
https://www.gocovrihcp.com/clinical-data/
Gocovrihcp.com

May 27th, 2020 - The efficacy and safety of GOCOVRI® 274 mg were evaluated in two Phase 3, randomized, placebo-controlled trials

Pain and dyskinesia in Parkinson's disease may share common pathophysiological mechanisms – An fMRI study
https://www.jns-journal.com/article/S0022-510X(20)30242-2/pdf
Journal of Neurological Sciences;

May 26th, 2020 - Parkinson's disease (PD) patients develop levodopa induced dyskinesia with disease progression from sensitization of central pathways. Pain pathways are also impacted with suggestions dyskinetic patients may process pain differently.

White matter hyperintensities and risk of levodopa‐induced dyskinesia in Parkinson’s disease
https://onlinelibrary.wiley.com/doi/full/10.1002/acn3.50991
Annals of Clinical and Translational Neurology;

Feb 6th, 2020 - To investigate whether the burden of white matter hyperintensities (WMHs) is associated with the risk of developing levodopa‐induced dyskinesia (LID) in Parkinson’s disease (PD).

Blood Flow and Glucose Metabolism Dissociation in the Putamen Is Predictive of Levodopa Induced Dyskinesia in Parkinson's Disease Patients
https://www.frontiersin.org/articles/10.3389/fneur.2019.01217/full
Frontiers in Neurology;

Nov 20th, 2019 - The forefront treatment of Parkinson's disease (PD) is Levodopa. When patients are treated with Levodopa cerebral blood flow is increased while cerebral metabolic rate is decreased in key subcortical regions including the putamen. This phenomenon ...

Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials
https://content.iospress.com/articles/journal-of-parkinsons-disease/jpd181565
Journal of Parkinson's Disease;

Jul 29th, 2019 - Evaluate prevalence of troublesome dyskinesia and OFF through the day, assessed by 30-minute intervals, as well as the mean number and duration of troublesome dyskinesia and OFF episodes, transitions between PD states, and effects of Gocovri® (ama...

see more →

Drugs  15 results see all →

Clinicaltrials.gov  10,129 results

"My Body Does Not Fit in Your Medical Textbooks": A Physically Turbulent Life With an U...
https://www.ncbi.nlm.nih.gov/pubmed/33620331
Advances in Mind-body Medicine; Snapp M

Feb 23rd, 2021 - The purpose of this article is to enhance our understanding of prayer healing by studying a case which was described as a 'remarkable healing' by a medical assessment team at the Amsterdam University Medical Centre (UMC) in the Netherlands. This r...

Association of autonomic symptoms with cerebrospinal fluid biomarkers in Parkinson dise...
https://doi.org/10.1097/MD.0000000000024837
Medicine Yu Z, Li Y et. al.

Feb 20th, 2021 - Dysautonomia is common in patients with Parkinson disease (PD) since disease early phase. Scales for Outcomes in Parkinson's disease - Autonomic (SCOPA-AUT) is a well-designed scale assessing the autonomic dysfunctions of PD patients. Our objectiv...

Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation...
https://doi.org/10.1016/j.parkreldis.2021.02.003
Parkinsonism & Related Disorders; Kopytova AE, Rychkov GN et. al.

Feb 20th, 2021 - Mutations in the glucocerebrosidase gene (GBA) encoding the lysosomal enzyme glucocerebrosidase (GCase) cause Gaucher disease (GD) and are the most commonly known genetic risk factor for Parkinson disease (PD). Ambroxol is one of the most effectiv...

Attitudes toward use and timing of deep brain stimulation: a patient's with DBS perspec...
https://doi.org/10.1016/j.clineuro.2021.106553
Clinical Neurology and Neurosurgery; Cabrera LY, Mitchell SD et. al.

Feb 20th, 2021 - To guide responsive policy and better understand factors that might shape patients' decisions to have DBS earlier, we explore perspectives and attitudes toward earlier deep brain stimulation (DBS) of Parkinson disease (PD) patients with DBS. Befor...

Tumor Necrosis Factor Inhibition and Parkinson Disease: A Mendelian Randomization Study.
https://doi.org/10.1212/WNL.0000000000011630
Neurology Kang X, Ploner A et. al.

Feb 20th, 2021 - To evaluate the effects of long-term tumor necrosis factor (TNF) inhibition on the risk and age at onset of Parkinson disease (PD), we performed a two-sample Mendelian randomization study using genome-wide association studies (GWAS) summary statis...

see more →

News  463 results

A Breakthrough in Parkinson Disease and New Data on Treating Stroke
https://www.medscape.com/viewarticle/933212

Jul 12th, 2020 - This transcript has been edited for clarity. Dear colleagues, I'm Christoph Diener, a neurologist from the University of Duisburg-Essen in Germany, presenting six very interesting publications from February 2020 in the fields of stroke, multiple s...

The Gut a New Therapeutic Target for Brain Disorders?
https://www.staging.medscape.com/viewarticle/931719

Jun 3rd, 2020 - Changes in the mucus that lines the gastrointestinal (GI) tract may contribute to bacterial imbalance in the gut and exacerbate core symptoms of autism, Parkinson disease (PD), Alzheimer disease (AD), and multiple sclerosis (MS), new research sugg...

The Gut a New Therapeutic Target for Brain Disorders?
https://www.medscape.com/viewarticle/931719

Jun 3rd, 2020 - Changes in the mucus that lines the gastrointestinal (GI) tract may contribute to bacterial imbalance in the gut and exacerbate core symptoms of autism, Parkinson disease (PD), Alzheimer disease (AD), and multiple sclerosis (MS), new research sugg...

Gocovri Clinical Data
https://www.gocovrihcp.com/clinical-data/
Gocovrihcp.com

May 27th, 2020 - The efficacy and safety of GOCOVRI® 274 mg were evaluated in two Phase 3, randomized, placebo-controlled trials

Pain and dyskinesia in Parkinson's disease may share common pathophysiological mechanisms – An fMRI study
https://www.jns-journal.com/article/S0022-510X(20)30242-2/pdf
Journal of Neurological Sciences;

May 26th, 2020 - Parkinson's disease (PD) patients develop levodopa induced dyskinesia with disease progression from sensitization of central pathways. Pain pathways are also impacted with suggestions dyskinetic patients may process pain differently.

see more →

Patient Education  13 results see all →